Related Experiment Video
Updated: May 21, 2026
12:03
In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis
Published on: December 9, 2016
Ewing's sarcoma: overcoming the therapeutic plateau
Vivek Subbiah1, Razelle Kurzrock
1Department of Investigational Cancer Therapeutics and Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, Texas 77030, USA. vsubbiah@mdanderson.org
Discovery Medicine
|June 30, 2012
Summary
Ewing sarcoma (EWS) targeted therapies show promise but face resistance. Combining IGF1R and mTOR inhibitors with chemotherapy may improve outcomes for high-risk EWS patients.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Ewing sarcoma (EWS) is a rare bone cancer primarily affecting young patients.
- The EWS/FLI1 chimeric gene resulting from t(11;22) translocation drives EWS development.
- Standard chemotherapy offers limited benefit for metastatic or relapsed EWS.
Purpose of the Study:
- To review current targeted therapy approaches for EWS.
- To explore strategies for overcoming therapeutic resistance in EWS.
- To discuss novel therapeutic agents and multimodal treatment integration for EWS.
Main Methods:
- Review of preclinical and clinical data on targeted therapies in EWS.
- Analysis of resistance mechanisms to IGF1R and mTOR inhibitors.
- Exploration of novel therapeutic strategies including multikinase and PARP inhibitors.
Main Results:
- Targeted therapies like IGF1R and mTOR inhibitors show dramatic responses in select EWS patients.
- Therapeutic resistance is a significant challenge in EWS treatment.
- Preclinical data support novel agents like multikinase and PARP inhibitors.
Conclusions:
- Combining targeted therapies with chemotherapy may enhance efficacy in high-risk EWS.
- Overcoming resistance through biomarker identification is crucial for EWS treatment.
- Integrating novel agents and multimodal approaches offers new strategies for EWS management.
